Study S000032

Efficacy and Safety of Ixekizumab or Ixekizumab Concomitantly Administered With Tirzepatide in Adult Participants With Moderate-to-Severe Plaque Psoriasis and Obesity or Overweight: A Phase 3b, Randomized, Multicenter, Open-Label Study (TOGETHER-PsO)

Included trial: extracted data ClinicalTrials.gov record

Registration

Registration: NCT06588283
Acronym: TOGETHER-PsO
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE3
Masking: NONE
Status: COMPLETED
Enrollment: 281
Start: 2024-09-30
Primary completion: 2026-01-08
Lead sponsor: Eli Lilly and Company
Conditions: Psoriasis; Obesity
Interventions: DRUG:Ixekizumab; DRUG:Tirzepatide
Results posted: FALSE
Individual participant data sharing: YES
Secondary identifiers: OTHER:I1F-MC-RHDC

Registered primary outcomes

Percentage of Participants Who Simultaneously Achieved Psoriasis Area and Severity Index (PASI) 100 and At Least 10% Weight Reduction [Baseline to Week 36]

Linked records (3)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0014237	Ixekizumab With or Without Tirzepatide in Adults With Psoriasis and Overweight or Obesity: A Phase 3b Randomized Clinical Trial. Lebwohl M, JAMA dermatology	2026	Randomized trial	PMID 42139049 DOI	cites ClinicalTrials.gov:NCT06588283; registry reference DERIVED:42139049
R0055156	Editorial: Exploring innovative therapies for rare inflammatory skin diseases Dennis Niebel, Frontiers in Medicine	2026	Nonrandomized study	PMID 41939760 DOI	cites ClinicalTrials.gov:NCT06588283
R0055833	24 \| IXEKIZUMAB WITH OR WITHOUT TIRZEPATIDE IN ADULTS WITH PSORIASIS AND OVERWEIGHT OR OBESITY: THE TOGETHER-PSO PHASE 3B RANDOMIZED CLINICAL TRIAL Associazione Dermatologi-Venereologi Ospedalieri Italiani e della Sanità Pubblica, Dermatology Reports	2026	Randomized trial	DOI	cites ClinicalTrials.gov:NCT06588283